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Seasonal influenza vaccines provide protection against matching influenza A virus (IAV)
strains mainly through the induction of neutralizing serum IgG antibodies. However,
these antibodies fail to confer a protective effect against mismatched IAV. This lack of
efficacy against heterologous influenza strains has spurred the vaccine development
community to look for other influenza vaccine concepts, which have the ability to elicit
cross-protective immune responses. One of the concepts that is currently been worked
on is that of influenza vaccines inducing influenza-specific T cell responses. T cells
are able to lyse infected host cells, thereby clearing the virus. More interestingly, these
T cells can recognize highly conserved epitopes of internal influenza proteins, making
cellular responses less vulnerable to antigenic variability. T cells are therefore cross-
reactive against many influenza strains, and thus are a promising concept for future
influenza vaccines. Despite their potential, there are currently no T cell-based IAV vaccines
on the market. Selection of the proper antigen, appropriate vaccine formulation and
evaluation of the efficacy of T cell vaccines remains challenging, both in preclinical and
clinical settings. In this review, we will discuss the current developments in influenza
T cell vaccines, focusing on existing protein-based and novel peptide-based vaccine
formulations. Furthermore, we will discuss the feasibility of influenza T cell vaccines and
their possible use in the future.
Keywords: influenza vaccines, T cell vaccines, influenza A virus, cross-reactive immune response, peptide
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Introduction
Several million people worldwide are infected with influenza viruses annually, which can result
in hospitalization and even death from complications in severe cases. Vaccination is the pre-
ferred method to prevent influenza virus infections. Two types of influenza, influenza A and B,
currently circulate among the human population. The influenza A virus (IAV), however, can be
further divided in several subtypes and strains. The surface of antigens of IAV, hemagglutinin
(HA), and neuraminidase (NA), frequently alter due to antigenic drift and sometimes alter due
to antigenic shifts. Seasonal influenza vaccines need to be updated accordingly to match the
circulating IAV strains. While seasonal influenza vaccines are effective against their matched IAV
strains, they are unable to cross-react with unmatched strains. The lack of cross-reactivity of
vaccine-elicited immune responses, mainly antibodies, is a major limitation of current influenza
vaccines.
Frontiers in Immunology | www.frontiersin.org May 2015 | Volume 6 | Article 2371
Soema et al. T cell-inducing influenza A vaccines
Several novel concepts for the development of cross-reactive
IAV vaccines have been pursued in recent years. One concept is
a vaccine that induces mucosal IgA responses, which can induce
strong cross-protective antibody responses against closely related
IAV strains (Figure 1). However, the cross-reactivity of these
IgA responses with respect to more divergent strains is modest
(1). Alternatively, vaccines that induce (IgG) antibody responses
against conserved antigens, such as HA stalk-reactive- or M2e-
specific antibodies, might be promising (2, 3). Studies, how-
ever, indicate that these approaches mostly lead to cross-reactive
responses within the same phylogenetic group of IAV, such as
H5N1 andH1N1 (4), with some exceptions (5, 6). Finally, vaccines
inducing influenza-specific T cell responses can offer broad and
long-lasting immune responses. Since T cells recognize epitopes
that are mostly derived from viral proteins located in the nucleo-
capsid, which are conserved between IAV strains, T cell responses
can be effective against a broad range of influenza strains. This
averts the necessity of seasonally changing the influenza vaccine
composition, and thus could be a significant improvement over
the current influenza vaccines. A drawback of a purely T cell-
inducing vaccine for the prevention of seasonal influenza could be
that, unlike IgA antibodies, T cell responses cannot prevent infec-
tion but prevent (severe) disease. For the application as a universal
vaccine, currently T cell responses are thought to have the highest
potential to induce such broad heterosubtypic responses that can
react to any IAV subtype.
Natural IAV infections induce, next to antibody responses,
T cell responses that are potentially cross-reactive. Indeed, it is
FIGURE 1 | Reactogenicity of immune responses against influenza
strains. Influenza A strains are displayed in their respective phylogenetic
groups. HA-specific IgG responses (orange) react only with homologous
influenza strains. Mucosal IgA responses (red) can provide heterosubtypic
reactivity against related influenza strains. Stalk- or M2e-specific antibodies
(blue) are cross-reactive within either group 1 or group 2 influenza strains.
T cells react universally against all influenza strains, regardless of subtype
or group.
assumed that memory T cell established by previous IAV infec-
tions prevent subsequent IAV infection in some instances; most
individuals experience severe IAV-induced symptoms only a few
times in their life. However, there are indications that the cytotoxic
T cell (CTL) activity of T cell recall responses wanes over times
in humans, suggesting that T cell responses established by IAV
infections can only protect for a few years (7). Additionally, the
number of available influenza-specific memory T cells should be
large enough to be able to rapidly respond to IAV infectionwithout
excess additional expansion of the T cell pool (8). Furthermore, it
is known that regulatory T cells suppress T cell responses during
IAV infections, which can have a negative effect on the subsequent
formation of a memory T cell pool (9). Natural IAV infections
therefore do notmount a T cell response potent enough to provide
long-lasting protection against all heterologous IAV strains. T cell-
inducing influenza vaccines might overcome this shortcoming
by establishing long-lasting, cross-reactive T cell responses. In
this review, we will focus on the latest developments in T cell-
inducing influenza vaccine research. The selection of antigen,
formulation and administration strategies, as well as possible risks
and limitations of T cell-inducing vaccines are evaluated.
CD8+ T Cells
Primed CD8+ T cells, otherwise known as CTLs, are able to lyse
influenza-infected cells. Via the endogenous antigen presentation
pathway, infected cells will present influenza-derived epitopes
on their cell surface, which are recognized by influenza-specific
CTLs. The CTLs then induce apoptosis of the target cell either
through the secretion of perforins and granzymes or through
the Fas ligand pathway. Furthermore, CTLs produce proinflam-
matory cytokines such as TNF-α and IFN-γ that exert antiviral
activity, which further aids viral clearance (10, 11).
Several recent studies have elucidated the importance of CD8+
T cells during IAV infections in humans. Sridhar et al. showed that
individuals who possessed a higher frequency of CD8+IFN-γ+IL-
2  T cells experienced a decreased clinical illness during infection
with pandemic 2009 H1N1 IAV (12). CD8+IFN-γ+IL-2  T cells
were correlated with a decreased risk of fever, an absence of
viral shedding and reduced influenza-like illness (ILI) symptoms.
These cells also expressed the lung-homing marker CCR5, which
might explain their effectivity. CD8+ T cells induced by seasonal
IAV strains were shown to be cross-reactive with several influenza
A strains such as 2009H1N1, swine-originH3N2, and the recently
emerged H7N9 IAV (13–15). Indeed, when cellular responses
were studied in individuals infected with pandemic 2009 H1N1
IAV, rapid recall responses of CD8+ T cells were observed, which
peaked within 1week after infection (16). These responses were
thought to originate from lymphoid memory CD8+ T cells estab-
lished from prior seasonal IAV infections. Memory T cells were
demonstrated to last for at least several years in a study, which
assessed IAV-specific T cell responses in PBMCs of individuals
collected from 1999 to 2012 (17). PBMCs from several donors
were stimulated with Resvir-9 (a H3N2 reassortant strain), and
IAV specificity andCTL activity were subsequently determined by
intracellular staining with several labeled, highly conserved CTL
peptides and IFN-γ.
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Taken together, these studies indicate that CD8+ T cells can
play a role in the protection against IAV infections, that these T
cells are long-lived and are able to cross-react with multiple IAV
strains. Thus, the induction of these T cells may be the basis of
broadly reactive universal influenza vaccines.
CD4+ T Cells
CD4+ T cells also play an important role in IAV infections, but
contrary to CD8+ T cells, have not been studied extensively yet
in humans. In animal models, activated CD4+ T cells can exert
different roles in relation to IAV infections. CD4+ T cells can
act as T helper cells (TH), providing costimulatory signals by
CD40/CD40L signaling to antigen presenting cells (APCs) during
the priming of B cells and CD8+ T cells (18, 19). Interestingly,
reactivation of adoptively transferred CD4+ TH (from IAV chal-
lenged mice) increased the recall capacity of both memory CD4+
and CD8+ T cell responses in receptive mice after IAV infection
(20).While CD4+ TH is not necessarily required for the induction
of effector CTLs, it is crucial for the transition of CD8+ T cells
to the memory phase, which is essential for the maintenance of
long-lived immunity (21, 22). Surprisingly, CD4+ T cells can also
acquire cytotoxic activity through the release of perforin in mice,
providing direct protection against IAV infection (23).
In humans, it was found that pre-existing CD4+ T cells were
reactive to pandemic 2009 H1N1 peptides, and were correlated
with lower virus shedding and reduced illness during IAV infec-
tion (24). Unexpectedly, CD8+ T cell responses were not asso-
ciated with reduced illness in this study. Nonetheless, it can be
concluded that preclinical and clinical studies indicate that tar-
geted induction of CD4+ T cell responses, next to CD8+ T cell
responses, may be an attractive goal for novel vaccines.
T Cell-Inducing Vaccines
Immune responses, and in particular, the antibodies elicited by
current seasonal influenza vaccines are limited in their effec-
tiveness against heterologous IAV infections. From the current
knowledge onT cell responses during IAV infections in preclinical
and clinical studies, as described above, it is believed that T cell-
inducing influenza vaccines have the potential to result in broadly
reactive, universal influenza A vaccines. While most vaccines
are still in preclinical development, a few concepts have recently
entered the clinical phase. In Table 1, the most recent develop-
ments in T cell-inducing vaccines are listed. Recently, the potency
of viral vector-based influenza vaccines has been reviewed (25). In
the following paragraphs, several other potential T cell-inducing
influenza vaccines are highlighted.
Live Attenuated Influenza Vaccines
Live attenuated influenza vaccines (LAIV) are currently on the
market as intranasal (i.n.) IAV vaccines. LAIV induce next to
humoral responses both CD4+ and CD8+ T cells in children
(26, 27). Remarkably, no cellular immune responses are detected
in adults receiving LAIV; the cause of this discrepancy might
be related to the naïve status of children. Furthermore, LAIV
are more effective than current seasonal trivalent inactivated
influenza vaccines (TIV) in children but not in adults, suggesting
that the induction of cellular immune responses increases the
efficacy of LAIV (48). The encapsulation of LAIV in a biopolymer
of alginate and subsequent subcutaneous (s.c.) administration-
induced CD8+ T cell responses that protected mice from a het-
erologous IAV challenge (49), indicating that LAIV can induce
T cell responses via immunization routes other than i.n. by use
of formulation strategies. The induction of cellular responses by
LAIVmight be explained by the “live” state of the vaccine antigen;
it can still infect after vaccination. During the viral replication,
many viral proteins containing CD8+ and CD4+ epitopes are
produced within the infected host cell, leading to efficient antigen
processing via the endogenous pathway, which leads toMHC class
I presentation and subsequent T cell activation.
Whole Inactivated Influenza Virus
Like LAIV, whole inactivated influenza virus (WIV) contains
internal proteins such as nucleoprotein (NP), matrix proteins 1
and 2 (M1 and M2, respectively), polymerase basic proteins 1
and 2 (PB1 and PB2, respectively) and polymerase acidic protein
(PA), which possess conserved T cell epitopes. WIV vaccines
were replaced by subunit and split vaccines due to incidence of
adverse events associated with WIV (50), but have been given
increased attention the past few years in the search for cross-
reactive vaccines (51). Improvements on WIV production and
purification methods have decreasedWIV-associated side effects,
making this vaccine acceptable for use again, especially for the
induction of broadly reactive immune responses. At normal clin-
ical dose, which typically does not exceed 15µg of HA protein,
WIV induces adequate neutralizing antibody titers, but generally
fail to induce any cellular responses regardless of administration
route (52). However, studies by Budimir et al. showed that mul-
tiple high doses of WIV, such as two times 6µg, were able to
induce significant amounts of IAV-specific CTLs in mice (53–55).
The critical roles of membrane fusion activity and the presence
of viral ssRNA for the induction of CTLs were established (53,
55). Intramuscular (i.m.) administration of WIV proved to be
more effective at inducing CTLs than i.n. administration (54).
This was confirmed by Takada et al., who found that intranasal
vaccination with WIV failed to induce T cell responses (56).
By contrast, one study utilizing gamma-irradiated WIV showed
that the protective effect of WIV was mainly mediated by T cell
responses (29). It is suspected that themethod ofWIV inactivation
can have an effect on its immunogenicity. Aside from increased
dosage, WIV-induced cellular responses can also be boosted by
the addition of adjuvants. For instance, a dose of 2.5µg WIV
adjuvanted with cationic lipid/DNA complex (CLDC) was able
to induce influenza-specific CD4+ and CD8+ T cell responses in
mice, whereas alum adjuvantedWIV only induced high-antibody
responses (57). Similar to studies with WIV, the addition of alum
to virosomes proved to be detrimental to cellular responses in
mice (58), since it skewed the TH to a TH2-type response.
Virosomes
Virosomal vaccines can also induce influenza-specific CTL
responses. The addition of adjuvants to virosomes is necessary
to induce T cell responses, since unadjuvanted virosomes only
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TABLE 1 | T cell-inducing influenza vaccines in recent development.
Class Concept name Antigen(s) Adjuvant(s) Immune response Status Reference
Whole virus
or protein
vaccine
Live attenuated influenza
vaccine
Live attenuated influenza vaccine
(various strains)
None Induces CD4+ and CD8+ T cell responses in
unprimed children
Licensed (26, 27)
Single-cycle live attenuated influenza
vaccine (H3N2)
None Induced CD8+ T cell responses in mice that
protected against heterologous challenge
Preclinical (28)
Gamma-irradiated whole
inactivated influenza vaccine
Whole inactivated influenza vaccine
(H3N2)
None Induces robust influenza-specific T cell responses in
mice
Preclinical (29)
Influenza virosomes Virosomes (H5N1) Matrix-M Induces good influenza-specific CD4+ T cell
responses in healthy adults, but CD8+ T cell
responses were limited
Phase I trials (30)
Multimeric-001 Synthetic protein containing B and
T cell epitopes from HA, M1, and NP
Montanide ISA 51VG Induces cellular responses in healthy adults and
elderly that are reactive against multiple IAV strains
Phase I trials (31, 32)
Peptide
vaccine
Lipopeptides Minimal T cell epitopes from M1, PA,
and NS1
Pam2Cys Induces CD8+ T cell responses that protect mice
against heterologous IAV challenge
Preclinical (33)
Minimal T cell epitopes from HA and
NP combined with seasonal
influenza vaccine
Pam2Cys Induces CD8+ T cell responses that reduces lung
viral load in mice after heterologous challenge
Preclinical (34)
Minimal T cell epitope from NP Phosphatidylserine Induces peptide-specific CD4+ and CD8+ T cell
responses in mice
Preclinical (35)
Liposome-conjugated
peptides
Minimal T cell epitopes from M1,
NP, PA, PB1, or PB2
Liposomes, CpG-ODN
5002
Induces T cell responses that protect mice from IAV
challenge
Preclinical (36, 37)
Peptide-loaded virosomes Minimal T cell epitope from M1 Virosome, CpG-ODN
1826
Induces peptide-specific CD8+ T cells that reduce
body weight loss of mice after heterologous IAV
infection
Preclinical (38)
FP-01.1 Long peptides containing T cell
epitopes from M1, NP, PB1, and
PB2
Peptides conjugated to
fluorocarbon moiety
Induces CD4+ and CD8+ T cells in healthy adults
that are cross-reactive against IAV-infected target
cells
Phase I trials (39)
Flu-v Long peptides containing T cell
epitopes from M1, M2, and NP
Montanide ISA 51VG Induces peptide-specific CD8+ T cells in healthy
adults
Phase I trials (40)
Virus-like
particle/viral
vector
vaccine
Peptide fused to PapMV
nanoparticles
T cell epitope from NP Papaya mosaic virus
nanoparticles
Induces peptide-specific CD8+ T cells in mice Preclinical (41)
DdFluM1 T cell epitopes from M1 Adenoviral
dodecahendron particles
Induces peptide-specific CD4+ and CD8+ T cells in
chickens
Preclinical (42)
PIV5-NP T cell epitope from NP Parainfluenza 5 Induces CD8+ T cells in mice that reduce morbidity
and lethality after IAV challenge
Preclinical (43)
MVA-NP+M1 T cell epitopes from M1 and NP Modified vaccinia virus
Ankara vector
Induces influenza-specific cellular responses in
healthy adults and elderly that reduce viral shedding
and reduction of symptoms
Phase II trials (44–46)
DNA vaccine DNA plasmids encoding for
T cell epitopes
DNA encoding for B and T cell
epitopes from HA and NP
None Induces T cell responses that reduce body weight
loss of mice after IAV challenge
Preclinical (47)
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induce humoral responses. The incorporation of LpxL1, a detoxi-
fied lipopolysaccharide, in virosomes significantly increased IFN-
γ secretion in mice (59). Madhun et al. showed that addition of
the saponin-based Matrix-M adjuvant to virosomes significantly
increased the production of TH1-associated cytokines IL-2 and
IFN-γ when administered i.m. to mice (60). Strikingly, a signifi-
cant induction of multifunctional CD4+ T cells was also observed
in amurinemodel after the addition ofMatrix-M to the virosomal
vaccine. In a similar study, Radosevic et al. screenedmultiple adju-
vants (i.e., aluminumphosphate, aluminumhydroxide,MF59, and
Matrix-M) in combination with virosomes in mice (61). Unlike
the study by Madhun et al., virosomes were readily able to induce
CD4+ T cells, and addition of any adjuvant, including Matrix-
M, did not increase these responses. However, only MF59 and
Matrix-M adjuvanted virosomal vaccines were able to induce IAV-
specific CD8+ T cell responses. Furthermore, addition of any
aluminum salt-based adjuvants proved to be ineffective at eliciting
any cellular responses, which was probably due to TH2-skewed
immune responses by aluminum salts.
The ability to induce cellular immune responses by some mar-
keted influenza vaccines is of great value in order to offer lim-
ited cross-reactivity against non-matched influenza strains. These
vaccine formulations can play a role as an intermediate solution
until the next generation of cross-protective influenza vaccines is
developed.
Peptide Antigens
Peptides are another type of antigen that can be used in T cell-
inducing influenza vaccines. However, short peptides that con-
sist of a minimal epitope are generally not immunogenic, and
thus require additional modification or formulation to be able to
induce T cell responses (62).
Several preclinical studies have used minimal epitope
peptides as their main antigen to induce influenza-specific
cellular responses. Short influenza peptides conjugated to
phosphatidylserine were able to induce CD8+ T cell responses in
mice (35). The conjugation of lipids to peptides opens up several
possibilities; a PA-derived peptide conjugated to Pam2Cys, a
lipid and TLR2 ligand, and efficiently induced peptide-specific
CTL responses in mice (63). Furthermore, peptides conjugated to
liposomes were able to minimize morbidity in IAV-infected mice
through the induction of CD8+ T cells (36, 37). Remarkably, these
peptide–liposome conjugates were able to induce CD8+ memory
T cells without the contribution of CD4+ T cells. Liposomes act
as a delivery system for the peptides, which are then internalized
more efficiently by APCs than unformulated peptides. Direct
conjugation of the peptide to a lipid or liposome is, however, not
required. NP366–374 peptide encapsulated in liposomes was able to
induce potent T cell responses whenmixedwith anti-CD40mAbs,
and reduced viral lung titers of influenza-infected mice (64).
Aside from liposomes, virosomes have also been used as deliv-
ery systems for short peptide antigens. These virosomes utilize
the membrane fusion activity of HA proteins to deliver the loaded
peptide to the cytosolic compartment of the APC. An early study
showed that virosomes loaded with the H-2Kd binding influenza
NP147–155 peptide-induced CTLs that were able to lyse IAV-
infected target cells (65). The addition of the adjuvant CpG-ODN
1826 to influenza M158–66 peptide-loaded virosomes was shown
to increase peptide-specific CD8+ T cell responses even further
(38), which resulted in a faster recovery of vaccinated mice after
heterologous influenza virus infection.
Long peptide vaccines consisting of multiple epitopes are,
opposed to short peptide vaccines, already in the clinical testing
phase. Flu-v consists of an equimolar mixture of four synthetic
polypeptides derived fromM1, M2, and NP IAV proteins, formu-
lated with the adjuvant Montanide (40). Flu-v-induced peptide-
specific T cells in healthy subjects; unfortunately, reactivity against
actual IAV strains was not determined. However, vaccination
studies in mice showed that CD8+ T cell responses induced by
Flu-v did reduce mortality after IAV infection (66).
Similar to Flu-v, FP-01.1 consists of six polypeptides derived
from M1, NP, PB1, and PB2, which were conjugated to a fluoro-
carbonmoiety. The vaccinewas able to induceCD4+ andCD8+ T
cells in healthy subjects (39). Moreover, these T cells were cross-
reactive with H1N1 and H3N2 IAV-infected target cells. This is
the first study that shows a peptide vaccine capable of inducing
cross-reactive T cells in humans, which is very encouraging for
the development of cross-reactive T cell-inducing vaccines.
The studies described above suggest that peptide-based
approaches are very promising in the development of T cell-
inducing IAV vaccines. However, an important challenge is the
genetic variability among the human population in relation to
epitope recognition and presentation. CD4+ and CD8+ T cells
recognize IAV epitopes displayed on MHC molecules, which are
called human leukocyte antigen (HLA)molecules in humans. Dif-
ferentHLApolymorphisms occur in the human genome, resulting
in a host of varying HLA molecules in the human population.
Each HLA can only bind specific viral epitopes, which means that
multiple epitopes of the same antigen need to be in a peptide-
based vaccine to cover the human population (67). In silico pre-
diction methods can be employed to determine the potential T
cell immunogenicity of conserved epitopes across multiple IAV
strains (68). Furthermore, several transgenic mouse strains have
been bred that express HLA molecules, which can be used in
preclinical development. Nonetheless, there remains a significant
challenge for peptide-based vaccines to include enough epitopes
to cover each HLA type, which would be required for a vaccine to
be effective in the entire population.
Other T Cell Influenza Vaccine Concepts
Aside from the vaccine strategies described above, several
other concepts are currently in clinical development (Table 1).
Multimeric-001 is a synthetic recombinant protein composed
of nine T cell and B cell epitopes derived from HA, NP, and
M1 influenza proteins (31). The vaccine in combination with
the adjuvant Montanide ISA 51VG was able to induce cellu-
lar responses in healthy subjects. The cellular responses showed
limited reactivity to multiple IAV strains. In a follow-up study,
the Multimeric-001 vaccine showed an induction of humoral
and cellular responses in elderly subjects similar to responses
observed in healthy adults (32). While the results of these studies
are encouraging, the true effectiveness of the induced cellular
responses against homologous and heterologous IAV infections
has yet to be determined.
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Another concept, which has advanced to the clinical stage of
development, is the modified vaccinia virus Ankara vectored vac-
cineMVA-NP+M1 (45). This vaccine consists of a vaccinia virus
Ankara expressing the influenza proteins NP and M1. Several
clinical trials, including a phase II study, were conducted with this
vectored vaccine. MVA-NP+M1 was able to expand pre-existing
memory CD8+ T cells in both healthy adults and elderly, and also
increased the IAV-specific CD4+ T cell population (44, 46).
T Cell-Based Influenza Vaccine Concepts in the
Clinical Phase
The protein-based influenza vaccines such as LAIV, WIV, and
virosomes currently have the advantage that they are already
licensed and have been widely used. Such vaccines might be
excellent candidates to prime naïve populations for both cellular
and humoral responses.
Peptide-based vaccine concepts have the advantage that they
can be easily engineered and produced synthetically. However,
as mentioned above, selection of the right epitopes remains vital.
These vaccines also require additional formulation with adjuvants
to increase their immunogenicity. Nonetheless, several peptide-
based vaccines have entered the clinical phase.
Vectored T cell-inducing vaccines are a sophisticated con-
cept. They include both antigen and adjuvant in a single par-
ticle. Since they express whole proteins rather than epitopes,
vectored vaccines might have a higher coverage among different
populations compared to peptide-based vaccines. A recent study
also combined a seasonal influenza vaccine with MVA-NP+M1
to increase the breadth of the immune response (69). Such an
approach is a major improvement and might be an ideal solution
to induce both humoral and cellular immunity with a single vac-
cine. Other concepts, such as peptide-based influenza vaccines,
are also eligible to be used simultaneously with seasonal influenza
vaccines, as demonstrated recently (34). This is a good step toward
a universal influenza vaccine.
Vaccine Priming
The IAV-naïve status and age of persons may influence the
immunogenicity of T cell-inducing IAV vaccines. This was already
observed with LAIV vaccines, which effectively induce cellular
responses in naïve children, but not induce such responses in
adults, who already established an immunological memory to IAV
(26, 27). A study in mice reported that CD8+ T cells primed by
LAIV rapidly differentiated to IAV-specific memory T cells after
short-interval boosting, and were able to protect against heterolo-
gous challenge (70). Several T cell-inducing vaccine concepts con-
sider the potency of the prime-boost approach; a DNA–protein
prime-boost concept enhanced the T cell responses to IAV inmice
(71), and in a clinical trial priming with Multimeric-001 before
a seasonal influenza vaccine boost greatly increased IAV-specific
cellular responses in elderly subjects (32). Priming at an early age
in naïve mice with IAV resulted in the induction of long-term
memory CD8+ T cells with the broadest reactivity, while priming
at an older age resulted in aCD8+ T cell populationwith a reduced
diversity (72). Thus, T cell priming at an early age, when the
subject is still naïve, should be considered before immunization
with an influenza vaccine that only induces humoral responses.
As a result, the intended target population of a vaccine is key for
vaccine design and development (73).
Resident Lung T Cells
Many T cell-inducing vaccine concepts aim for the induction
of systemic IAV-specific T cell responses. However, local T cell
responses at the site of IAV infection are potentiallymore effective.
The presence of IAV-specific residentmemory T cells (TRM) in the
lungs was correlated with clearance of heterologous IAV infection
in mice (74). CD4+ T cells mediated the formation of CD8+ TRM
cells, adding yet another important function for CD4+ TH (75).
Current knowledge on the establishment of TRM cells has been
reviewed recently (76). While the process of TRM induction is not
completely unraveled, some possiblemechanisms can be exploited
to induce IAV-specific TRM responses with vaccines. A recent
study specifically targeted an antigen to resident lung DCs using
antibodies, and were able to generate IAV-specific CD8+ TRM
cells in mice that provided protection against a lethal influenza
challenge (77). Furthermore, it is known that CXCR3-expressing
CD8+ T cells play an important role in the establishment of CD8+
TRM cells in the lungs (78). The near future may learn us whether
specific targeting of certain T cell populations, e.g., by adjusting
the route of administration to the lungs (79, 80), may add to the
potential of T cell-inducing influenza vaccines.
Preclinical Cellular Correlates of Protection
There is clear evidence that cellular responses correlate with a
reduction of symptoms after IAV infection. However, current
correlates of protection (CoP) for influenza vaccines are all based
on the induction of antibodies, such as the presence of hemag-
glutination inhibition- or virus neutralization titers, which are
inadequate CoPs for T cell-inducing vaccines. Instead, responses
that indicate the presence of effector T cells such as IFN-γ and
IL-10 cytokines, combined with cytotoxic effector molecules like
granzyme B may be more suitable as CoP for T cell-inducing
vaccines (81). These parameters also need to be further evaluated
in epidemiological studies in order to define their efficacy. For
instance, it is still unclear what quantitative levels of IAV-specific
CD8+ or CD4+ T cell responses are required for protection
against an IAV challenge. Furthermore, an adequate translation
from animal models to the human setting has to be made. While
there is quite some experience with humoral responses against
IAV in animal models and their relation to the clinic, such experi-
ence has not been established yet for cellular responses. Establish-
ing these responses as humanCoPs, and translating study findings
from animal models to humans remain important tasks for the
development of T cell-inducing IAV vaccines.
Concerns and Limitations of
T Cell-Inducing IAV Vaccines
There are some concerns whether IAV-specific T cells can provide
the same level of protection compared to IAV-specific antibodies.
While T cells have a broader reactivity, they can only recognize
and lyse IAV-infected host cells. Most likely, an IAV infection is
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already spreading before an efficient T cell response is mounted.
It can therefore be debated whether T cells responses actually
provide protection (i.e., sterilizing immunity) or only shorten
the length and severity of influenza symptoms (i.e., decreased
morbidity). The difference between these two can be very hard
to distinguish. Therefore, elucidation of T cell responses after
influenza infection in humans is of critical importance to deter-
mine the efficacy of T cell-inducing influenza vaccines. Nonethe-
less, reduction of morbidity of IAV infections would already be
a great success in situations where seasonal influenza vaccines
would be ineffective, such as a mismatched influenza epidemic
or an influenza pandemic. The definition of protection should
therefore not only be limited to sterilizing immunity but also to
reduction of disease morbidity.
Another concern is the possibility of excessive T cell responses
to IAV infections, which could cause immunopathology in the
lungs (82). There are indications that excessive T cell responses
mediate severe lung inflammation and subsequent lung damage
after IAV infection in mice. Only one study describes the phe-
nomenon in humans; elevated IAV-specific CD8+ and CD4+
T cell responses were found in pandemic 2009 H1N1-infected
children with severe pneumonia (83). It was, however, unclear
whether these T cell responses were the cause of pneumonia or
simply present due to the infection.
It is yet unknown whether T cell-inducing influenza vaccines
can mount long-lasting T cell responses after a limited number
of immunizations. As already discussed above, natural IAV infec-
tions are able to induce T cell responses, but their effectivity is
limited. Studies suggest that local inflammation and inflammatory
cytokine production caused by IAV infection suppress CD8+ T
cell responses in mice. This was partly attributed to an increased
expression of PD-L1 on theCD8+ T cells, which cripples the func-
tionality of these T cells (84, 85). T cell-based vaccines, however,
should not experience the effects of these immunosuppressive
pathways, since inflammation after immunization is generally
limited. It is thus likely that these vaccines can induce T cell
responses, which are more potent than those elicited by natural
IAV infections. Nonetheless, it is important that T cell-inducing
vaccines elicit balanced T cell responses, and special interest
should be given to T cell-mediated immunopathology during
safety studies of these vaccines.
Aside from the intensity of T cell responses, special attention
should be given to the selection of target epitopes derived from
IAV. A recent study described the existence of tolerizing epitopes
in certain influenza strains, which are recognized by autologous
regulatory T cells and may suppress protective T cell responses
(86). Another study found that T cells against certain immun-
odominant epitopes such as M158–66 have a poor functionality,
and are unable to clear IAV-infected cells (87). It was hypothesized
that these immunodominant epitopes are actually a decoy of IAV
to evade T cell-mediated immunity and to prevent the generation
ofmore potent T cells against other epitopes. It is therefore impor-
tant that such epitopes, which could lead to decreased or impotent
T cell responses, are identified and excluded in any prospective T
cell-inducing IAV vaccines.
Conclusion
Humoral immune responses elicited by current IAV vaccines do
not provide sufficient cross-protection against non-matched IAV
infections. IAV-specific T cells recognize conserved epitopes of
IAV and thus have to potential to be cross-protective. Many dif-
ferent T cell-inducing vaccines are currently under development,
and some have even reached clinical phases. Selecting suitable
preclinical testing models and clinical CoPs are vital for further
development of such vaccines. In addition, proper understanding
the effectiveness of each T cell response and their possible patho-
logical effects is of great importance. The current developments
with T cell-inducing IAV vaccines, including novel formulations
and extended immunological insight, are fast evolving and may
ultimately result in universal influenza vaccines.
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